Gilead Oncology Trodelvy Dosing and Administration | GileadPro

This website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the United Kingdom.

Oncology Prescribing Information

The recommended dose of Trodelvy® is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles1


Watch this short video to learn more about how to appropriately dose and administer Trodelvy®.

References
  1. Trodelvy® UK Summary of Product Characteristics. Gilead Sciences Ltd. Available at: https://www.medicines.org.uk/emc/product/12880. Accessed May 2025.
Stay up to date

Receive email updates from Gilead, including promotional communications.

Register

May 2025 UKI-TRO-0275

Adverse events should be reported

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.